Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongqing Zuo

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
NPJ Precision Oncology|December 10, 2025
Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trialKai Tian, Yafei Jiang, Mengxiong Sun, et al.
International Journal of Cancer|February 6, 2019
Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcomaGangyang Wang, Mengxiong Sun, Yafei Jiang, et al.
Journal of Cellular and Molecular Medicine|September 15, 2016
Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathwaysDongqing Zuo, Zifei Zhou, Hongsheng Wang, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Etoposide activates CD8<sup>+</sup> T cell anti-tumor immunity in osteosarcoma through MHC I upregulation via tumor-secreted IL-33 mediated signalingXin He, Hanjun Li, Haoyu Wang, et al.
Cell Reports. Medicine|February 21, 2025
Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcomaHaoran Mu, Qi Zhang, Dongqing Zuo, et al.
Nature Communications|November 23, 2022
Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatmentYafei Jiang, Jinzeng Wang, Mengxiong Sun, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
NPJ Precision Oncology|December 10, 2025
Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trialKai Tian, Yafei Jiang, Mengxiong Sun, et al.
International Journal of Cancer|February 6, 2019
Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcomaGangyang Wang, Mengxiong Sun, Yafei Jiang, et al.
Journal of Cellular and Molecular Medicine|September 15, 2016
Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathwaysDongqing Zuo, Zifei Zhou, Hongsheng Wang, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Etoposide activates CD8<sup>+</sup> T cell anti-tumor immunity in osteosarcoma through MHC I upregulation via tumor-secreted IL-33 mediated signalingXin He, Hanjun Li, Haoyu Wang, et al.
Cell Reports. Medicine|February 21, 2025
Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcomaHaoran Mu, Qi Zhang, Dongqing Zuo, et al.
Nature Communications|November 23, 2022
Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatmentYafei Jiang, Jinzeng Wang, Mengxiong Sun, et al.
Pageof 5